Raloxifene ['Evista'] does not increase the risk of cardiovascular events in postmenopausal women with osteoporosis, according to 3-year data from the MORE*trial which were presented recently at the 50th Scientific Session of the American College of Cardiology [Orlando, US; March 2001]. In fact, if anything, the drug showed a positive, but nonsignificant, trend towards a reduction in cardiovascular events. The data are in contrast to HERS*, which showed no overall benefit and some evidence of an early risk of thrombotic events in high-risk women who received estrogen or combined hormone replacement therapy (HRT).**Furthermore, preliminary data from the WHI*have indicated that HRT is associated with a possible increase in the risk of cardiovascular events.†